Cargando…
Conceptual Framework of the Design of Pleiotropic Drugs against Alzheimer’s Disease
The multifactorial nature of some diseases, particularly neurodegenerative diseases such as Alzheimer’s disease, frequently requires the use of several drugs. These drug cocktails are not without drawbacks in terms of increased adverse effects, drug–drug interactions or low adherence to treatment. T...
Autores principales: | Guiselin, Thomas, Lecoutey, Cédric, Rochais, Christophe, Dallemagne, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610275/ https://www.ncbi.nlm.nih.gov/pubmed/37896142 http://dx.doi.org/10.3390/pharmaceutics15102382 |
Ejemplares similares
-
Development of Novel Potential Pleiotropic Compounds of Interest in Alzheimer’s Disease Treatment through Rigidification Strategy
por: Lecoutey, Cédric, et al.
Publicado: (2021) -
First Synthesis of Racemic Trans Propargylamino-Donepezil, a Pleiotrope Agent Able to Both Inhibit AChE and MAO-B, with Potential Interest against Alzheimer’s Disease
por: Guieu, Benjamin, et al.
Publicado: (2020) -
Inhibiting Acetylcholinesterase to Activate Pleiotropic Prodrugs with Therapeutic Interest in Alzheimer’s Disease
por: Toublet, François-Xavier, et al.
Publicado: (2019) -
A Novel in vivo Anti-amnesic Agent, Specially Designed to Express Both Acetylcholinesterase (AChE) Inhibitory, Serotonergic Subtype 4 Receptor (5-HT(4)R) Agonist and Serotonergic Subtype 6 Receptor (5-HT(6)R) Inverse Agonist Activities, With a Potential Interest Against Alzheimer’s Disease
por: Hatat, Bérénice, et al.
Publicado: (2019) -
Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT(4) receptors activities for the treatment of Alzheimer’s disease
por: Lalut, Julien, et al.
Publicado: (2020)